NCT07310420 2026-03-11A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast CancerTerSera Therapeutics LLCPhase 1 Not yet recruiting88 enrolled